KB
Kostas Biliouris BMO Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Sarepta Therapeutics
SRPT
$1.9B
| $18.16 | $50 |
175%
upside
| Market Perform | 1 month ago |
|
2
Alnylam Pharmaceuticals
ALNY
$58.5B
| $447 | $360 |
19%
downside
| Outperform | 2 months ago |
|
3
Rocket Pharmaceuticals
RCKT
$354M
| $3.24 | $8 |
147%
upside
| Outperform | 3 months ago |
|
4
Avidity Biosciences
RNA
$5.99B
| $47.23 | $72 |
52%
upside
| Outperform | 5 months ago |
|
5
Dyne Therapeutics
DYN
$1.92B
| $13.50 | $50 |
270%
upside
| Outperform | 5 months ago |
|
6
Ionis Pharmaceuticals
IONS
$9.16B
| $57.49 | $45 |
22%
downside
| Market Perform | 6 months ago |
|
7
Intellia Therapeutics
NTLA
$1.22B
| $11.40 | $50 |
339%
upside
| Outperform | 7 months ago |
|
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.25B
| $17.27 | $35 |
103%
upside
| Outperform | 11 months ago |
|
9
4D Molecular Therapeutics
FDMT
$288M
| $6.14 | $40 |
551%
upside
| Outperform | 1 year ago |
|
10
Legend Biotech
LEGN
$6.41B
| $34.22 | $90 |
163%
upside
| Outperform | 1 year ago |
|
11
Beam Therapeutics
BEAM
$1.66B
| $16.31 | $57 |
249%
upside
| Outperform | 1 year ago |
|
12
BridgeBio Pharma
BBIO
$9.89B
| $50 | $37 |
26%
downside
| Market Perform | 1 year ago |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $59.09 | $100 |
69%
upside
| Outperform | 1 year ago |
|
14
Prime Medicine
PRME
$578M
| $3.12 | $19 |
509%
upside
| Outperform | 1 year ago |
|
15
CRISPR Therapeutics
CRSP
$4.79B
| $52.66 | $98 |
86%
upside
| Outperform | 3 years ago |
|